Is Acalabrutinib a BTK inhibitor?

Acalabrutinib (Acalabrutinib) is a BTK (brutinib) inhibitor. BTK is a tyrosine kinase that belongs to the tyrosine kinase family. It mainly exists in B cells and is a key component of the B cell signaling pathway. BCell signaling pathways regulate the survival, proliferation and differentiation of B cells under normal circumstances, but in some hematological malignancies, such as chronic In lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), this channel is abnormally activated, leading to excessive growth of cancer cells.

Acotinib's mechanism of action involves selective inhibition of BTK, thereby blocking a key step in the B cell signaling pathway. It interferes with the activation of downstream signaling molecules by binding to BTK and preventing its activation, thereby inhibiting abnormally active B cells and slowing or stopping the growth and spread of malignant tumor cells.

Compared with otherBTKinhibitors, acotinib has higher selectivity, which means that it interferes with the signaling channels of cancer cells more precisely and reduces the adverse effects on normal cells. This high degree of selectivity helps reduce toxic side effects during treatment and improves patient tolerance.

Overall, acotinib, as a BTK inhibitor, has shown good efficacy in the treatment of specific types of hematological malignancies, providing patients with an effective and relatively safe treatment option.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.